Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 1;5(12):1802-1804.
doi: 10.1001/jamaoncol.2019.4328.

Association Between Aspirin Use and Biliary Tract Cancer Survival

Sarah S Jackson  1 , Ruth M Pfeiffer  1 , Zhiwei Liu  1 , Lesley A Anderson  2 , Huei-Ting Tsai  3   4 , Shahinaz M Gadalla  1 , Jill Koshiol  1
Affiliations

Association Between Aspirin Use and Biliary Tract Cancer Survival

Sarah S Jackson et al. JAMA Oncol. .

Erratum in

  • Error in the Figure.
    [No authors listed] [No authors listed] JAMA Oncol. 2019 Dec 1;5(12):1811. doi: 10.1001/jamaoncol.2019.5657. JAMA Oncol. 2019. PMID: 31830216 Free PMC article. No abstract available.

Abstract

This database study analyzes the association between aspirin use and survival in patients with biliary tract cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.
Figure.. Adjusted Survival Curves Among Postdiagnosis Aspirin Users and Nonusers by Cancer Site
Survival curves were weighted by age and sex distributions of the cohort with aspirin use modeled as time dependent. In patients with gallbladder cancer, the survival probabilities were for aspirin users vs nonusers were 59% (95 CI, 31%-100%) vs 27% (95% CI, 16%-47%). The survival probabilities in aspirin users vs nonusers with cholangiocarcinoma were 62% (95% CI, 42%-98%) 26% (95% CI, 19%-35%). In patients with ampulla of Vater cancer, the survival probabilities were 85% (95% CI, 33%-83%) vs 52% (95% CI, 18%-43%) in aspirin users vs nonusers, respectively. Survival probabilities in aspirin users vs nonusers with overlapping lesions of the biliary tract were 57% (95% CI, 34%-100%) vs 27% (95% CI, 16%-46%). Estimated survival at 1 year after diagnosis (dotted line) was calculated with 95% CIs computed based on the quantiles of the corresponding bootstrap distribution function with 1,000 replications. The numbers at risk represent individuals at the beginning of each time point.
See this image and copyright information in PMC

Comment in

References

    1. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99-109. - PMC - PubMed
    1. Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943-962. doi:10.1158/2159-8290.CD-17-0245 - DOI - PMC - PubMed
    1. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK, Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer. 2011;105(8):1107-1113. doi:10.1038/bjc.2011.289 - DOI - PMC - PubMed
    1. Gasic GJ. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev. 1984;3(2):99-114. doi:10.1007/BF00047657 - DOI - PubMed
    1. Therneau TM, Crowson CS, Atkinson EJ. Adjusted survival curves. 2015; https://cran.r-project.org/web/packages/survival/vignettes/adjcurve.pdf. Accessed April 8, 2019.

MeSH terms

Substances